Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

This study is testing whether combining targeted radiation therapy with a checkpoint inhibitor immunotherapy drug (IMSA101) can improve outcomes for people with metastatic kidney cancer (clear cell renal cell carcinoma) that is progressing in only a small number of sites (called oligoprogression). **You may be eligible if...** - You have metastatic clear cell renal cell carcinoma (the most common type of kidney cancer) - Your cancer is progressing in 5 or fewer sites (oligoprogression) - All progressing tumour sites can be safely treated with radiation - You have at least one tumour site that can safely receive an injection of IMSA101 - You are 18 or older and have a reasonable performance level (Karnofsky score at least 50%) - Your organ and blood function are adequate **You may NOT be eligible if...** - You have tumours that are progressing in an area near the central airways of the chest that is too dangerous to radiate Talk to your doctor to see if this trial is right for you.